Pertuzumab adds 16 months survival to trastuzumab plus chemo for HER2positive breast cancer

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=YyzykYSZ6so

Visit http://www.ecancer.org for more. • At a press conference at ESMO 2014, Dr Swain (Washington Cancer Institute, Washington, USA) presents the findings of the phase 3 'CLEOPATRA' study which found that patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone.

#############################